RxDoctor Payments Data

Geoffrey Bergman, MD

Interventional Cardiology · New York, NYNPI 1982791075

Payments from drug & device makers

What this record shows

15 manufacturers reported payments, led by Abbott at 29.8% of the total. Reporting peaked in 2023 at $3,463 and has fallen 72.7% since, to $947 in 2025.

$11,835in general payments, 2019–2025

Across 153 payments — averaging $77.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Boston Scientific$3K
  • Edwards Lifesciences$2K
  • Medtronic$1K
  • Philips North America LLC$739
  • Biocardia, Inc.$324
  • plus $449 from 9 others
$204,852in research payments, 2019–2025

Across 93 payments — averaging $2202.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$168K
  • Edwards Lifesciences$20K
  • Boston Scientific$17K
  • Medtronic$55

What the payments were for

  • Travel & lodging$5,28745%
  • Food & beverage$6,54855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,835 in reported general payments places this provider in the 55th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$242,414
Medicare patients
370
Services billed
1,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$14,842
FarxigaDapagliflozin Propanediol16$13,466
Metoprolol Succinate44$699
Rosuvastatin Calcium38$536
ClopidogrelClopidogrel Bisulfate40$497
Ezetimibe27$437
Losartan Potassium33$321
Amlodipine Besylate11$184
Atorvastatin Calcium16$117
Carvedilol18$97
Furosemide27$84

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →